Associated Banc Corp Acquires 3,567 Shares of Johnson & Johnson $JNJ

Associated Banc Corp raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,170 shares of the company’s stock after purchasing an additional 3,567 shares during the quarter. Associated Banc Corp’s holdings in Johnson & Johnson were worth $27,659,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Clayton Financial Group LLC purchased a new position in Johnson & Johnson in the third quarter worth about $28,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Semmax Financial Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC raised its holdings in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after buying an additional 184 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 1.9%

Shares of JNJ opened at $213.78 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $515.06 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 2.15 and a beta of 0.34. The company has a 50-day moving average of $203.88 and a 200 day moving average of $185.81. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $215.18.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.04. The firm had revenue of $23.99 billion during the quarter, compared to the consensus estimate of $23.73 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.42 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s payout ratio is 50.19%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware’s top court threw out part of a roughly $1 billion damages award tied to J&J’s 2019 attempt to buy Auris Health and ordered a recalculation — a development that could materially reduce the company’s payout and legal overhang. Johnson & Johnson’s $1 billion loss from robotics takeover reduced by Delaware top court
• Positive Sentiment: J&J reported encouraging long-term Rybrevant results in metastatic colorectal cancer — positive oncology data can raise expectations for revenue and pipeline value in oncology. Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
• Positive Sentiment: MedTech momentum is cited as a near-term growth driver, led by cardiovascular strength and new product ramps — this supports revenue upside ahead of J&J’s Q4 results. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: New depression data (CAPLYTA, SPRAVATO and other analyses) to be presented at ACNP may improve perceptions of J&J’s CNS franchise and long-term drug commercialization prospects. Johnson & Johnson elevates leadership in depression with new data at 2026 ACNP
• Neutral Sentiment: Management’s presentation at the J.P. Morgan Healthcare Conference was published (transcript) — useful for investor modeling but largely reiterates strategy and pipeline priorities rather than new surprises. J&J Presents at 44th Annual J.P. Morgan Healthcare Conference (Transcript)
• Neutral Sentiment: Investor-letter / market commentary pieces note J&J’s strong Q4 contributions as part of broader market trends; these confirm momentum but add little incremental catalyst. Here’s What Lifted Johnson & Johnson (JNJ) in Q4
• Negative Sentiment: Despite the Delaware ruling reducing part of the award, residual legal exposure remains until damages are fully recalculated and any further appeals conclude — some uncertainty and potential liability persist. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Negative Sentiment: Analysts flag lingering China market pressure for MedTech/pharma sales, which could temper near-term international growth even as other regions recover. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wolfe Research lifted their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Guggenheim increased their price objective on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.